Metabolic Effects of Adjuvant Recombinant Human Growth Hormone in Patients With Continuing Sepsis Receiving Parenteral Nutrition
- 1 July 1998
- journal article
- clinical trial
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 22 (4) , 199-205
- https://doi.org/10.1177/0148607198022004199
Abstract
Background: Adjuvant growth hormone is advocated for treating the catabolism of prolonged sepsis not corrected by parenteral nutrition alone. Methods: An open study was performed in which eight patients whose postabsorptive resting energy expenditure was persistently elevated by a mean of 19% as a result of continuing sepsis were randomized to receive 0.03 or 0.06 mg/kg recombinant human growth hormone (rhGH) each evening for 7 days adjuvant to total parenteral nutrition. Plasma concentrations of growth hormone, insulin, insulin-like growth factors 1 and 2 (IGF-1 and -2) and their binding proteins IGFBP-1 and -3 were measured before and after rhGH, and their relationship with rates of whole-body protein turnover was determined in the morning in the postabsorptive state by using L-[1-13C]leucine. Results and Conclusions: Before rhGH, the patients were hyperinsulinemic (mean, 44.4 mU/L) but had growth hormone levels within the normal range (< 10 mU/L). After the seventh dose of rhGH, nocturnal growth hormone concentrations rose to a mean of 35.3 ± 26.1 and 61.3 ± 21.05 mU/L for the low and higher dose groups, respectively. Morning IGF-1 concentrations showed a small increase during treatment, rising from a mean of 241.3 ± 99.0 to 301.7 ± 167.3 ng/mL for the low-dose group and from 214.5 ± 74.6 to 294.1 ± 116.9 ng/mL for the higher-dose group. IGF-2 increased slightly by 89 ± 39 and 75 ± 49 ng/mL for the low and higher doses, respectively. IGFBP-1 and -3 and insulin did not change. The balance between nitrogen input and urinary urea nitrogen increased after rhGH by a mean of 5.3 g/d with no differences between the two dosage groups (4.74 ± 1.56 g/d for the higher dose, 5.94 ± 3.70 g/d for the lower). No significant changes were observed in whole-body protein turnover after a 1-week course of rhGH. (Journal of Parenteral and Enteral Nutrition 22:199-205, 1998)Keywords
This publication has 22 references indexed in Scilit:
- Growth hormone therapy for protein catabolismQJM: An International Journal of Medicine, 1996
- The Rationale for the Use of Recombinant Human Growth Hormone and Insulin-Like Growth Factor-I for Catabolic Conditions in HumansHormone Research, 1996
- Role of Insulin-Like Growth Factors and Growth Hormone in Reversing Catabolic StatesHormone Research, 1992
- ORCADIAN VARIATION OF GH‐INDEPENDENT IGF‐BINDING PROTEIN IN DIABETES MELLITUS AND ITS RELATIONSHIP TO INSULIN. A NEW ROLE FOR INSULIN?Clinical Endocrinology, 1988
- Pulsatile Secretion of Fuel-Regulatory HormonesDiabetes, 1987
- Whole body protein metabolism in parenterally fed patients: Glucose versus fat as the predominant energy sourceClinical Nutrition, 1987
- The grading of sepsisBritish Journal of Surgery, 1983
- Relationship of plasma leucine and α-ketoisocaproate during a L-[1-13C]leucine infusion in man: A method for measuring human intracellular leucine tracer enrichmentMetabolism, 1982
- Quantitation of 2-ketoacids in biological fluids by gas chromatography chemical ionization mass spectrometry ofO-trimethylsily-quinoxalinol derivativesJournal of Mass Spectrometry, 1981
- New methods for calculating metabolic rate with special reference to protein metabolismThe Journal of Physiology, 1949